万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/
3、投稿网址：
https://mc.manuscriptcentral.com/cancerbiotherapy
4、官网邮箱：kcloudhansen@liebertpub.com（编辑部）
5、期刊刊期：一年出版10期。
2022年1月11日星期二
投稿须知【官网信息】
Cancer Biotherapy and Radiopharmaceuticals
For Authors
Manuscript Submission Guidelines
View General Guidelines
Journal Information
Manuscript Submission Site: https://mc.manuscriptcentral.com/cancerbiotherapy
Editorial Office Contact: kcloudhansen@liebertpub.com
Support Contact: prosupport@liebertpub.com
Journal Model: Hybrid (Open Acess Option)
Blinding: Single Blind
File formatting requirement stage: Upon submission
Instant Online Option (immediate publication of accepted version): No
Submission Fee: $50.00. Click here to purchase your submission token.
Average time to initial decision: 18 days
About the Journal
Cancer Biotherapy and Radiopharmaceuticals invites original contributions on all research related to furthering the study of cancer therapeutics and research at the intersection of that therapy with radiopharmaceuticals for both diagnostic and therapeutic applications. The mission of the journal is to communicate advances in fields including biotherapy, targeted drug and radionuclide delivery, nanotechnology, and studies that advance the understanding of the mechanism of action and response of cancer to therapeutics. It is the expectation of this journal that all of the biological, chemical, and radiochemical tools be rigorously applied, characterized appropriately with the results of the studies in submitted manuscripts supported by the application of both rigorous controls and wherever appropriate, statistics. If you are uncertain if your work falls within the scope of the journal, please email the title and abstract of the paper to the editorial office prior to submission.
Manuscript Types and Guidelines
Original Articles
Comprehensive complete accounts of significant studies should be submitted as Original Articles (the majority of submissions fall under this category).
3,000-word limit
Structured abstract of no more than 200 words
Maximum total of ten (10) figures and/or tables
Maximum of 100 references
Uncropped western blots must be uploaded as supplemental data.
Review Articles
Suitable review articles that fall within the purview of the journal may introduce readers to topics of current interest or provide comprehensive updates to specific fields and topics that fall within the purview of the journal. Reviews should provide a concise overview of fundamental topics and translational issues. Reviews should be accessible to the broad readership of Cancer Biotherapy and Radiopharmaceuticals.
5,000-word limit
Abstract of no more than 250 words
Maximum total of ten (10) figures and/or tables
Maximum of 150 references
Uncropped western blots must be uploaded as supplemental data.
Short Reports
Technical Notes or Short Reports are a third category that is intended to provide publication of brief transformative techniques and methodology that researchers will potentially find of value and use in their respective laboratories. These are, by their nature, intended to be brief and concise (2-3 journal pages), yet fully informative to facilitate immediate use of the related information.
1,200-word limit
Abstract of no more than 100 words
Maximum total of five (5) figures and/or tables
Maximum of 10 references
Uncropped western blots must be uploaded as supplemental data.
……
更多详情：
https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/for-authors
